Evidence map›Paper›PMID 29740729›Full record

ArticleInternal and emergency medicine2018

A novel flash glucose monitoring system in patients with diabetes mellitus type 1 and 2: which are the pieces of evidence for payer decision-makers?

Salvatore Corrao, Biagio Nativo, Giuseppe Natoli, Marika Lo Monaco, Francesco Perticone

Abstract read
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salvatore CorraoDepartment of Internal Medicine, National Relevance and High Specialization Hospital Trust, ARNAS Civico, Di Cristina, Benfratelli, Piazza Nicola Leotta 2, 90127, Palermo, Italy. s.corrao@tiscali.it.ORCID http://orcid.org/0000-0001-5621-1374
Biagio NativoDepartment of Endocrinology, Gravina Hospital, Caltagirone, Italy.
Giuseppe NatoliDepartment of Organizational, Clinical, and Translational Research, I.E.ME.S.T, Palermo, Italy.
Marika Lo MonacoDepartment of Organizational, Clinical, and Translational Research, I.E.ME.S.T, Palermo, Italy.
Francesco PerticoneDepartment of Medical and Surgical Sciences, "Magna-Græcia" University of Catanzaro, Catanzaro, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A rigorous health technology assessment is necessary to evaluate a new technology. However, healthcare regulatory agencies have less restrictive rules about medical devices, despite some recent warnings about this relevant matter. The evaluation should have at least two key issues, which require attention. The first one is its effectiveness, and the second one is its economic sustainability. In this paper, we deal with a novel glucose-sensing technology as a case study to examine the matter in depth. An evidence-based point of view is used to highlight this important issue.

Indexed as

Blood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansMonitoring, PhysiologicOutcome Assessment, Health CareTechnology Assessment, BiomedicalBlood GlucoseBiomedicalBiomedical technologyDecision makingEconomicEthicsOrganizationalTechnology assessment

Identifiers

PMID29740729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.